Events
-
2024/12/10 SHINE
Locally-Developed Gene Editing Technology Cures Boy with Serious Blood Disorder
A 14-year-old boy with serious thalassemia has recovered due to a locally-developed innovative gene editing technology, the Children's Hospital of Fudan University said on Monday.
-
2024/12/05 Correctseq
CorrectSequence Therapeutics to Participate in the 66th ASH Annual Meeting and Exposition
Dec 5, 2024, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical stage biotechnology company aims to use the innovative gene editing technology to help people with severe diseases, announc
-
2024/07/22 Correctseq
The First Clinical Gene Editing Therapy to Treat An Overseas Patient in China
On July 20, 2024, Shanghai, China, CorrectSequence Therapeutics Co., Ltd. (Correctseq) announced a significant milestone in their base editing therapy CS-101 for transfusion-dependent β-thalassemia. U
-
2024/07/19 Correctseq
CS-101 Clinical Result Included in EHA2024 Scientific Congress Report
Recently, the European Hematology Association (EHA) released the EHA2024 Scientific Congress Report titled "EHA Perspectives on Emerging Technologies in Hematology". As the world's firs
-
2024/06/06 Correctseq
CorrectSequence Therapeutics to Participate in EHA2024 Hybrid Congress
June 6, 2024, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical stage biotechnology company aims to use the innovative gene editing technology to help people with severe diseases, announ
-
2024/06/03 Correctseq
CorrectSequence Therapeutics to Participate in BIO International Convention 2024
May 29, 2024, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical stage biotechnology company aims to use the innovative gene editing technology to help people with severe diseases, announ
-
2024/04/13 Correctseq
April 12, 2024, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical stage biotechnology company aims to use the innovative gene editing technology to help people with severe diseases, anno
-
2024/04/02 Correctseq
CorrectSequence Therapeutics’ (Correctseq’s) base editing drug "CS-101 Injection" targeting transfusion-dependent β-thalassemia has obtained IND approval from the National Medical Products Administration (NMPA) of China on April 2, 2024 (acceptance number: CXSL2400021). This is the Chinese first base editing therapy with β-thalassemia. Correctseq is initiating the Phase 1 clinical study for CS-101 (clincialtrials.gov reference # NCT06291961).